Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
β-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
Gene Therapy Stops Bleeding in Hemophilia Single injection had durable effectiveness, study showed Dec 08, 2020
Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disorders Success with investigational use of gene editing in sickle cell disease, beta-thalassemia Dec 06, 2020
Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
JAK Inhibitor Wins in Second-Line Chronic GVHD Twice as many patients achieved a response at week 24 Dec 05, 2020
Sickle Cell Disease Tied to Worse COVID-19 Outcomes Black patients seem to be at higher risk for certain COVID-19 complications, death Dec 05, 2020
Three-Drug Regimen Reduces Myeloma Treatment Burden Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
Survival Bump With Oral AML Maintenance Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
Study: Adding Aspirin to DOAC? Better Have a Good Reason Combination tied to marked increase in bleeding risk Dec 09, 2019
'Off-the-Shelf' Therapy Active After CAR T-Cell Failure Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
Study Bolsters Case for Novel Xarelto Formulation for Kids Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories Dec 07, 2019
Chemo-Free Tx Tops Best Option in Younger CLL Patients Improved overall survival and safety with ibrutinib-based therapy Dec 04, 2018
Combination Regimen Extends PFS in Myeloma Large benefit but relevance of comparator questioned Dec 04, 2018
$2 Test Could Transform Sickle Cell Dx in Africa May have applications in high-income countries as well Dec 04, 2018
ASH Offers Early Look at Updated SCD Guidelines Experts formulated >50 recommendations on sickle cell disease Dec 03, 2018
Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies Studies test addition of targeted agents, immunotherapy Dec 03, 2018
Novel Therapies Offer Hope in Sickle Cell Disease Studies explore possibility of parental donor; boosting fetal hemoglobin production Dec 02, 2018
CAR T-Cell Responses Prove Durable in ALL, DLBCL Two studies demonstrate long-term control in relapsed/refractory disease Dec 01, 2018
Cutting Chemo Cycles Feasible in Younger DLBCL Patients Patients, ages 18-60, fare well with four cycles of CHOP instead of six Dec 01, 2018
Sneak Peek at Practice-Changing Research From ASH 2018 "Big trials, big results," plus sickle cell disease and CAR T-cell therapies Nov 30, 2018
Mixed Results with Regimens for Older AML Patients Positive data with venetoclax, liposomal cytarabine-daunorubicin Dec 14, 2017
Amyloidosis Treatments Miss the Heart of the Problem Only modest improvement in end organ function Dec 07, 2016
Bangladesh-Boston Collaborate on ASCT Center Two dozen patients undergo successful stem cell transplant in Dhaka Dec 05, 2016
Can Patients With Stable CML Stop Drug Therapy? Studies examine TKI cessation and dose reduction Dec 04, 2016
Survival Boost With Liposomal Tx in Older AML Patients Agent may also provide a bridge to successful transplant Dec 04, 2016
